The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. The emergence of GIP receptor (GIPR)-GLP1 receptor (GLP1R) co-agonists has fostered growing interest in the actions of GIP and GLP1 in metabolically relevant tissues. Here, we update concepts of how these hormones act beyond the pancreas. The actions of GIP and GLP1 on liver, muscle and adipose tissue, in the control of glucose and lipid homeostasis, are discussed in the context of plausible mechanisms of action. Both the GIPR and GLP1R are expressed in the central nervous system, wherein receptor activation produces anorectic effects enabling weight loss. In preclinical studies, GIP and GLP1 reduce atherosclerosis. Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection. We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPR-GLP1R co-agonist tirzepatide, as well as the GIPR antagonist-GLP1R agonist AMG-133. Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigati…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The peptide was further shown to lower blood pressure, reduce lipid, blood uric acid and transaminase levels, and alleviate hepatic lipid accumulation89.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [89]
In the citing paper
“A recent Phase 2 study, comprising 248 overweight and obese Chinese subjects, documented a body weight reduction of ~11.3% from baseline following 24 weeks of mazdutide treatment at the highest dose89.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [89]
In the citing paper
“Tirzepatide is a single molecule that combines glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonism13 resulting in synergistic effects on appetite, food intake, and metabolic function.14,15,16”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [15]
In the citing paper
“Agonism of each incretin receptor has different, often complementary effects on body weight and energy metabolism (Fig. 2) [5, 23, 104–107].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [106]
In the citing paper
“GIP also stimulates bone formation and inhibits bone resorption [38]”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [38]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Humans treated with GLP1RAs exhibit reduced food intake and weight loss, supporting the approval of liraglutide and semaglutide for weight loss in people with overweight or obesity 24,25,146 .”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Tirzepatide achieved double-digit percent total body weight loss in the SURPASS trials in people with T2DM 146 and more than 20% placebo-subtracted body weight loss in people with obesity treated with 15 mg once weekly in the SURMOUNT-1 trial 168 .”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Humans treated with GLP1RAs exhibit reduced food intake and weight loss, supporting the approval of liraglutide and semaglutide for weight loss in people with overweight or obesity 24,25,146 .”
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“Clinical studies examining the actions of liraglutide and semaglutide in people with NASH demonstrated reduction of inflammation without progression of fibrosis, as inferred from liver biopsies taken before and after therapy with GLP1RAs 39,94 .”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 3×
“GLP1RAs reduce systemic and tissue inflammation in mice, often independent of changes in body weight 79,80 , through poorly understood mechanisms 23 .”
Self-citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 5×
“Clinical studies examining the actions of liraglutide and semaglutide in people with NASH demonstrated reduction of inflammation without progression of fibrosis, as inferred from liver biopsies taken before and after therapy with GLP1RAs 39,94 .”
InfluentialKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“In large prospective studies of individuals with T2DM, GLP1RAs have not yet been shown to meaningfully reduce renal outcomes, beyond reduction of albumin excretion 107 .”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 3×
“Hospitalization for heart failure is also reduced by ~11% with GLP1RAs in cardiovascular outcome trials 26 .”
InfluentialSingle-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550
Research works printed but not linked: 1
- Ast, J., Broichhagen, J. & Hodson, D. J. Reagents and models for detecting endogenous GLP1R and GIPR. eBioMedicine 74, 103739 (2021).
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationWadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Metadata
- Authors
- Hammoud, R., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Nature Reviews Endocrinology
- Published
- 2022-12-12
- Volume
- 19
- Issue
- 4
- Pages
- 201-216
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4311182072
- Cited by
- 244
- References
- 191
- Citations by year
- 2026: 58 · 2025: 76 · 2024: 60 · 2023: 50
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (15432_1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, GIP receptor, GLP-1 receptor, glucose homeostasis, lipid homeostasis, liver, skeletal muscle, adipose tissue, central nervous system, anorectic effect, weight loss, obesity, type 2 diabetes, tirzepatide, atherosclerosis, cardiorenal protection, immune system, kidney, heart
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Pancreas, Receptors, Gastrointestinal Hormone, Weight Loss, Receptors, G-Protein-Coupled, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. https://app.cochat.ai/papers/10.1038/s41574-022-00783-3
- The paper
- Hammoud, R., & Drucker, D. J. (2023). Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00783-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.